摘要
目的探讨阿奇霉素序贯用于小儿支原体肺炎治疗的疗效-成本。方法选择2014年5月到2015年5月我院儿科收治的126例小儿支原体肺炎患者作为研究对象,随机分成实验组和常规组,每组各63例。两组均采用阿奇霉素治疗,实验组采取序贯法:静脉滴注2d后再口服序贯给药3d,常规组采取静滴法即连续静脉滴注给药5d。观察比较两组患者的临床疗效、成本以及不良反应发生率。结果治疗后实验组患者的临床有效率96.82%与常规组患者的临床有效率95.25%没有明显差异,没有统计学意义(P>0.05);实验组的不良反应发生率(19.05%)显著低于常规组的不良反应发生率(46.03%),实验组的总成本181.46±42.63显著低于常规组的总成本378.82±74.43,并且差异比较显著,具有统计学意义(P<0.05);结论阿奇霉素序贯用于小儿支原体肺炎治疗的临床疗效较好,成本较低,安全性好。
Objective To investigate the curative effect of azithromycin for cost-treatment of children mycoplasma pneumonia. Methods One hundred and twenty-six children with mycoplasma pneumonia who were admitted to our Department of Pediatrics between May 2014 and May 2015 were randomized into experimental group （n = 63） and routine treatment group （n = 63）. Patients in both groups were on azithromycin. The experimental group received sequential therapy, i.e., 2-day intravenous drip followed by 3-day sequential oral administration, whereas the routine treatment group received intravenous drip, i.e., continuous intravenous drip for five days. Patients were observed and compared between both groups regarding the clinical efficacy, cost and incidence of adverse reactions. Results After treatment, no significant difference in clinical response rate was noted between experimental group and routine treatment group （96.82% vs. 95.25%, P〉0.05）. The incidence of adverse reactions was significantly lower in the experimental group than in the routine treatment group （19.05% vs. 46.03%）, and so was the total cost [（181.46±42.63） vs. （378.82±74.43）], with a statistically significant difference （P〈0.05）. Conclusion Azithromycin sequential therapy in treatment of mycoplasma pneumonia in children is characterized by good clinical efficacy, low cost and good security.
出处
《国外医药（抗生素分册）》
CAS
2016年第3期134-136,共3页
World Notes on Antibiotics
